4baseCare, a Bengaluru-based precision oncology startup, has raised ₹90 crore in the first close of its Series B round, backed by veteran Indian investors Ashish Kacholia and Lashit Sanghvi, with continued participation from existing backer Yali Capital. The capital will be used to scale hospital-linked genomics testing and expand the company’s AI-driven clinical platform internationally.
Funding to Drive India expansion and international reach
The infusion comes amid rising demand for personalised cancer care in India and other emerging markets. 4baseCare plans to deploy the funds to strengthen its genomics testing infrastructure across Indian hospitals and accelerate market entry in the Middle East, Southeast Asia, Latin America and Central Asia—regions where precision oncology adoption is nascent but accelerating.
Addressing gaps in population-relevant genomic data
Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare develops clinico-genomic datasets that combine genetic and clinical information tailored to local populations. This strategy tackles a persistent problem in oncology: most genomic reference datasets are biased toward Western populations, which can reduce the accuracy of diagnostic interpretation and treatment selection for patients in Asia and other underrepresented regions.
Integrating genomics into hospital workflows
Rather than offering standalone tests, the startup embeds its genomics and data solutions into hospital care pathways, enabling oncologists to view advanced molecular insights alongside routine clinical records. The company emphasises long-term partnerships with healthcare institutions, positioning itself as a clinical intelligence partner that supports treatment decision-making and care coordination.
Scaling the AI platform OncoTwin Insights
A central component of 4baseCare’s proposition is OncoTwin Insights, an AI-enabled platform that analyses complex genomic and clinical datasets to generate evidence-based treatment recommendations. The platform helps clinicians identify targeted therapies, match patients to clinical trials and define personalised care pathways based on an individual’s molecular profile.
With the new funding, 4baseCare intends to enhance OncoTwin’s AI models, shorten report turnaround times and broaden clinical use cases across multiple cancer types, strengthening the platform’s utility for practising oncologists and research collaborators.
Investor confidence and strategic priorities
The participation of established investors such as Ashish Kacholia and Lashit Sanghvi, alongside renewed support from Yali Capital, signals market confidence in 4baseCare’s business model, technology stack and execution capabilities. Company executives say the funding will help attract specialised talent, speed product development and deepen partnerships with hospitals and research organisations globally.
Implications for precision oncology in emerging markets
The raise underscores growing investor interest in healthcare ventures that integrate genomics, artificial intelligence and clinical workflows. As India confronts a rising cancer burden, technologies that enable earlier detection, more accurate diagnosis and tailored treatment decisions are increasingly critical.
By prioritising population-specific data and scalable hospital integration, 4baseCare aims to make precision oncology more accessible and clinically relevant in India and other emerging markets where standard genomic resources and advanced diagnostics remain limited.
